thalidomide has been researched along with Peritonitis in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Peritonitis: INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide was administered orally at a dose of 100 mg/kg three times per week." | 5.35 | Thalidomide suppresses sclerosing encapsulating peritonitis in a rat experimental model. ( Aloisi, C; Buemi, M; Crisafulli, C; Cuzzocrea, S; Di Paola, R; Mazzon, E; Mondello, P; Mondello, S, 2009) |
| "Thalidomide was administered orally at a dose of 100 mg/kg three times per week." | 1.35 | Thalidomide suppresses sclerosing encapsulating peritonitis in a rat experimental model. ( Aloisi, C; Buemi, M; Crisafulli, C; Cuzzocrea, S; Di Paola, R; Mazzon, E; Mondello, P; Mondello, S, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| da Silva, YK | 1 |
| Augusto, CV | 1 |
| de Castro Barbosa, ML | 1 |
| de Albuquerque Melo, GM | 1 |
| de Queiroz, AC | 1 |
| de Lima Matos Freire Dias, T | 1 |
| Júnior, WB | 1 |
| Barreiro, EJ | 1 |
| Lima, LM | 2 |
| Alexandre-Moreira, MS | 2 |
| Mondello, S | 1 |
| Mazzon, E | 1 |
| Di Paola, R | 1 |
| Crisafulli, C | 1 |
| Mondello, P | 1 |
| Buemi, M | 1 |
| Aloisi, C | 1 |
| Cuzzocrea, S | 1 |
| dos Santos, JL | 1 |
| Lanaro, C | 1 |
| Gambero, S | 1 |
| Franco-Penteado, CF | 1 |
| Wade, M | 1 |
| Yerigenahally, S | 1 |
| Kutlar, A | 1 |
| Meiler, SE | 1 |
| Costa, FF | 1 |
| Chung, M | 1 |
3 other studies available for thalidomide and Peritonitis
| Article | Year |
|---|---|
Synthesis and pharmacological evaluation of pyrazine N-acylhydrazone derivatives designed as novel analgesic and anti-inflammatory drug candidates.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Arthritis; Ear; Edema; Female; Freund's Adjuvant; Hyd | 2010 |
Thalidomide suppresses sclerosing encapsulating peritonitis in a rat experimental model.
Topics: Animals; Anti-Infective Agents; Blotting, Western; Chlorhexidine; Disease Models, Animal; Enzyme Act | 2009 |
Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms.
Topics: Acetic Acid; Analgesics; Anemia, Sickle Cell; Animals; Anti-Inflammatory Agents; Antisickling Agents | 2011 |